To assess experimentally the FOXM1-suppressing effect of the STL001 in solid cancer, we used a panel of human solid tumor-derived cell lines with high FOXM1 expression levels, including ovarian cancer (OVCAR-8, ES-2), colorectal cancer (HCT-116, HCT-FET), esophageal cancer (FLO-1), hormone receptor-positive (TAM-R) and triple negative (HCC-1143) breast cancers, and prostate cancer (22Rv1, LNCaP). This evidence concerns the gene NR4A1 and breast cancer.